Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial

Fig. 1

– Overview of patient survival and progression. (A) Survival after therapy with hrBMP4 depicted in a swimmer plot, TMZ = temozolomide, RT = radiotherapy. Treatment modalities and survival duration before treatment with hrBMP4 are also shown. (B) Kaplan-Meier estimates of OS and (C) PFS in months. (D) Mean ADC on preoperative MRI in patients with and without early tumor progression after hrBMP4 treatment. Median intensity of E BMPR1A, F BMPR1B, G BMPR2 in tumor tissue before treatment with hrBMP4 in relation to the OS of the respective patients. Representative images form patient 3 (orange) and patient 1 (blue) of staining with H BMPR1A, I BMPR1B and J BMPR2 and the respective negative-control samples only stained with secondary antibody

Back to article page

Molecular Cancer

ISSN: 1476-4598